Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Contract/Agreement, Product/Service

Serum Institute Selects ABEC for Large-Scale, Single-Use COVID-19 Vaccine Manufacturing


ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is supporting Serum Institute of India Pvt. Ltd. (SIIPL) in Pune, India by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax' COVID-19 vaccine candidate, NVX?CoV2373. Serum Institute, the world's largest vaccine manufacturer by number of doses, will utilize ABEC's single-use technologies to advance a global supply of NVX?CoV2373 throughout India and low- and middle-income countries.

Serum Institute's new facility will be the largest single-use bioreactor-based vaccine manufacturing line in the world. ABEC's 4,000L CSR single-use bioreactors are the largest in the industry by a factor of two, allowing Serum Institute to double productivity per unit floorspace and achieve the lowest possible cost per dose. Leveraging its global presence, ABEC is manufacturing the single-use bioreactors and disposable containers (DC) in its US and Ireland facilities to meet Serum Institute's accelerated schedule. ABEC's multi-site global ISO-7 cleanrooms ensure a robust supply chain with the industry's shortest DC lead times, enabling Serum Institute to begin production in early 2021.

"We are proud to be a part of Serum Institute's urgent work to supply the Novavax COVID-19 vaccine," said Scott Pickering, ABEC President and CEO. "This critical project exemplifies and is enabled by all of the core values that ABEC is built on ? integrity, credibility, knowledge leadership, flexibility, and long-term commitment."

About ABEC

Since 1974, ABEC has been a global leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. The majority of the world's pharmaceutical and biotech companies are ABEC customers; with many of today's leading therapies manufactured by processes and equipment engineered, manufactured, installed, and serviced by ABEC. ABEC's unique value is based on long experience, complete in-house capabilities, a custom, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC's turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. To learn more about ABEC, visit abec.com, email [email protected] and follow us on LinkedIn.


These press releases may also interest you

at 17:31
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness. Moreover,...

at 17:00
Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private...

at 16:46
Darling Ingredients Inc. announced today that it will host a conference call on Thursday, April 25, 2024, at 9 a.m. Eastern Time (8 a.m. Central Time) to discuss first quarter 2024 financial results, which will be released earlier that day, and...

at 16:45
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic...

at 16:45
Geron Corporation , a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection...

at 16:35
DermTech, Inc. (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring...



News published on and distributed by: